<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 330 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page329.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=330">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 330 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 330</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=330"><img src="../thumb/330.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.1.2                                                      2020-04 / 293
       Contraindications: Diabet.coma, ketoacidos., sev. infects., stress,   ser.infect./trauma/low cal. intake, annual vit.B12 estimat., monit.bld.   Dosage: Titr.indiv.to optim.glycaem.control. Admin. 15 min.pref.
       trauma, sev.condits.where the biguanide unlikely to contr.hypergly-  gluc. dur,concom.sulphonylurea ther., poss. hypoglycaem.with com-  bef.main meals
       caem., sev.imp. ren./hepat.funct., heart fail., recent MI, dehydrat.,   bin.ther., stabilis.pts in hosp. if concom.insulin admin.  Init.recomm.start.dos: 0,5 mg.allow 1-2 wks.betw. titr.steps. Maint.:
       alcohol., condits.likely to predispos.to lactic acidos., chron.hypox.lung   Warnings: Reduc.incid.of lactat.acidos.by assess. assoc.risk fact.  Max.recomm.sngl.dos: 4 mg. Tot.max.dly.dos: 16 mg.
       dis., pregn., lactat., use in childr.und.12 yrs.not recomm.  Drug interactions: Alcoh.intoxicat.incr.lact. acidos. risk, ACE in-  Transf.from other oral hypoglycaem. Recomm. max.start.dos.:
       Side effects: GI disturbs., metal.taste, weight loss, lact.acidos.,   hibit.decr.bld.gluc.lev., reduc. ren. clear.with cimetidine, activ.of   1 mg bef.main meal.
       hypoglycaem.with sulphonylurea / insul/alcohol, metabol.acidos.  warfar.dimin., hypoglycaem. with sulphonylur., Vit.B 12 mal-absorpt.  Ther.in combinat.with metformin: Maint.with metformin dos.&
       Special precautions: Combinat.ther.assoc.with incr.CV mort.,   MINIDIAB, Pfizer [P/S]  admin. concom.0,5 mg 3xdly.
       monit.ren.funct.regul., monit.bld. gluc.dur.concom.sulphonylurea   Ther.in combinat.with insulin: If necess.titrat. insulin dos.accord.
       ther., stabilis.pts.in hosp.if concom.insulin admin., concom.anticoags.  Glipizide.  to therapeut.respons.as given in prod.lit.as a bedt.dos.for pts.control.
                                     Indications: Type 2 diabet.mellit./adult onset diabet.mellit.not
       Drug interactions: Vit. 12 absorpt.impair., reduc. ren. clear.with   on max. repaglinide dos.
       cimetidine. Alcohol.          contr. by diet alone.        Contra-indications: Type 1 diabet, diabet. ketoacidos. with/
                                     (S3) TABS. L/21.2/248.
       METFORMIN XR 500 MG ACCORD, Accord [P/S]  743666-003: 5 mg, 100, R400,55  without coma, childr., sev.ren.& hepat.impairm., concom.gemfi-
                                                                  brozil, pregn.& lactat.
       Metformin HCl.                Dosage: No fix.regimen. Init.recomm.dos.2,5 mg 30 mins.bef.   Side-effects: Hypoglycaem.reacts., vis.disturbs., GI disturbs, rarely
       Indications: Type 2 diab.mellit.in adults esp.in overweight pts.  breakf./midday.meal. Titrat.: Dos. adjustm.in increm.of 2.5-5 mg   sev.hepat.dysfunct., hypersens. reacts., vasculit.
       when diet managem.& exerc.alone do not result in adeq.glycaem.  determin.by bld. gluc. lev. Allow sev.days to pass betw.increm. If   Special precautions: Concom.rifampicin, elderly, imp.ren./hepat.
       control. May be given alone as init.ther./can be admin.in combinat.   sngl.dos.not satisfact.div.dos.should prove eff. Max. recomm.sngl.  funct., assess dos.& adherence to diet/exerc.bef.classif.as second.fail.,
       with other oral antidiabet.agents/insul.  dos.is 15 mg. Admin.dos.above 15 mg in 2 div.dos.bef.meals. Max.  combinat. ther. with thiazolidenediones not avail., incr. hypoglycaem.
       (S3) PROLONG.REL.TABS, 52/21.2/0090,  recomm.dos. 30 mg    risk when combin.with metform./ insulin, loss of glycaem.control in
       3000810-001: 500 mg, 60, R25,20  Contraindications: Insul.depend.diabet., diabet. ketoacidos., dia-  stress condits., no clinic.stud. in childr& adolesc.&lt;18 yrs./pts.&gt; 75 yrs.
       Dosage: Swallow whole, do not crush/chew/ break.  bet.coma, sev.hepat./ren.insuff., pregn. & lactat., safety & effic.in   theref.not recomm., incr.CV mortality, reg. monit. of bld.& urine gluc.lev.
       Usual start.dos.is 1 tab.dly with even.meal. Aft. 10-15 days dos.  chidr.not est., lact.intol.  Drug interactions: Clear.poss.alt.by any med. influenc.cytochrome
       should be adjust.on basis of bld. gluc.measurem. Slowly incr.dos.  Side effects: Sev.hypoglycaem., GI disturbs., headache, trem., dizz.,   P450 enzymes by inhibit./ induct., hypoglycaem.eff.enhanc.by gem-
       may improve GI tolerabil. Max.recomm.dos: 4 tabs.dly. Incr.in increm.   confus., drowsin., shakin., coma, allerg.skin reacts.incl.eczema, ery-  fibrozil/ clarithromyc./itraconazole/ketoconaz./trimethoprim/other
       of 500 mg every 10-15 days up to max. 2 000 mg once dly.with even.  thema, morbilliform/ maculopapular reacts., prurit., photosens.re-  antidiab.agents/MAOI/ß-block.agents/ ACE-inhibit./NSAID’s/sa-
       meal. If glycaem. control not achiev.with 4 tabs once dly consid.   acts., eye.disords & chang.in accomodat., cholestat.jaund., hepat.   licylates/alcohol/ octreotide & anabol.ster, rifampicin acts both
       2 tabs.2xdly admin.with food. If glycaem.control still not achiev.  disords., bld. dyscras., hepat.porphyr., porphyr.cutanea tarda., disul-  as induc.& inhibit.of Novonorm metabol., reduc. hypoglycaem.eff.
       consid.switch.to std.metform. tabs. with max.dos of 3 000 mg dly.  firam-like react., hyponatrem., malaise, hypersens.  with OC’s/rifampicin/barbit./ carbamazepine/thiazides/corticoster./
       Switch.pts.already treat.with metform.tabs: The start.dos.of   Special precautions: Incr.CV mortal.as compar. to ther.with diet   danazol/thyroid hormones & sympathomimetics, ß-block.agents may
       500 mg XR prolong.release tabs.should be equiv.to the dly.dos.of   alone/diet with insul., G6PD-defic., poss.lack of contr.when stabilis.  mask sympts. & body’s respon.to hypoglycaem., alcohol may inten-
       metform. immed. release tabs. Pts.treat.with metform at a dos.  pts.expos.to fev./ trauma/infect.or surg., imp.ren./hepat.funct., el-  sify & prolong hypoglycaem.eff.
       above 2 000 mg dly.are not recomm.to switch.to Metformin XR   derly, debilitat., malnourish., discont.treatm.if cholestat.jaund.occurs,
       500 mg Accord.                adren./pituit.insuffic., concom. ß-blocks., defic.calor.intake, aft.sev./   PIOGLITAZONE HYDROCHLORIDE TABLETS MACLEODS,
       Contraindications: Ac.metabol.acidos., diab. ketoacidos.,diabet.   prolong. exercise, alcoh., gluc.low.meds., poss. second. fail.due to   (Activo) Macleods [P/S]
       pre-coma, ren.fail./dysfunct., ac. condits.with potent.to alt.ren.funct.  diab.progress./dimin.med. respons., observ.pts.caref.(1-2 wks.) when   Pioglitazone
       eg. dehydrat/ sev.infect./shock/intravasc.admin.of iodinat. contrast   transf. from chlorpropamide.  Indications: Adjunct to diet & exercise in Type 2 diab. either as
       agents, ac./chron.dis.poss. caus.tiss.hypox.e.g. decompen.card./  Drug interactions: Hypoglycaem.eff.incr.with miconaz./fluconaz./  monother./in combinat.with metformin, a sulphonylurea or insulin
       resp.fail./ pancreatit./rec.MI/shock, hepat.insuffic., ac.alcoh. in-  NSAID’s/alcoh./salicylates/ß-block./ACE-inhibit./cimetidine/MAOI   when diet &/ exerc.& sngl.agent result inadeq.glycaem.control.
       toxicat., alcohol., pregn.    & high.prot. bound meds., hyperglycaem.poss.with danazol/ pheno-  (S3) TABS, 46/21.2/0257, 0258
       Side effects: Freq: Taste disturbs., N&V, diarrh., abdom.pain, loss of   thiaz./corticoster./sympathomimet./progestog./ thiaz.& other diu-  3000543-001: 15 mg, 30, R92,36
       appetite. Less freq: Lact. acidos., decr.Vit. B 12 absorpt.dur.longt.ther.,   ret./thyroid. meds./estrog./ OC/ phenytoin/nicotin.acid/Ca chann.  3000544-001: 30 mg, 30, R155,08
       erythema, prurit., urticar. Isolat.reports: LFT abnormalit., hepatit  block. meds. & isoniaz.  Dosage: Indiv. Take once dly.without regard to meals.
       Warnings and special precautions: Discont.& hospitalis.if me-  MYLAN METFORMIN 500; 850,1000, Mylan [P/S]  Monother: Init.15 or 30 mg once dly. Incr.if necess. in increm.
       tabol.acidos.suspect., reduc.incid. of lactat.acidos.by assess.assoc.  Metformin HCl.  to max.45 mg once dly. Consid. combin.ther.if no adeq.respons.
       risk fact.eg. poor. controll.diab./ketosis, prolong.fast./excess. alcoh.   Indications: Adults: Type II diab.mellit when diet. managem.&   Combinat.ther: Sulphonylur: Init.15 or 30 mg once dly.in com-
       intake/hepat.insuffic.& other condits. assoc. with hypox., reg.monit.  exerc.do not result in adeq. glycaem. control. Admin.alone as init.  binat.with curr.dos.of sulphonylur. Decr. sulphonylur.dos.in case
       of card.& ren.funct. in stable chron.heart fail., monit.ren.funct.bef.   ther./combin. ther. with antidiabet.med.or with insul.  of hypoglycaem.
       init. treatm.& reg.thereaft.esp.condits.where ren. funct.alt., discont.  Childr.& adolesc: Monother./in combinat.with insul. in childr.over   Metformin: Init.15 or 30 mg once dly.in combin. with current
       ther.bef.intravasc.admin.of iodinat. contrast agents allow.48 hr.interv   12 yrs with type II diabet.  metformin dos.
       & re-eval. ren. funct.bef.re-comm.ther., discont.48 hrs. bef.elect.surg.  (S3) FC TABS, 33/21.2/0204, 0205, 45/21.2/0669  Insulin: Init.at 15 or 30 mg once dly.in combin. with current insulin
       with gen.anaesthes.& reinstit.not earlier than 48 hrs aft., poss.hy-  897957-033: 500 mg, 90, R39,43  dos. In case of hypoglycaem./ plasma gluc. conc. decr.to less than
       poglycaem.with concom. insulin/ sulphonylureas & repaglinide,   897957-016: 500 mg, 500, R220,10  5,5 mmol/dL, decr. either insul. or pioglitazone dos. Furth. adjustm.
       stabilis. pts.on combin.ther.in hosp., reg.diabet. monit.tests, contin.  897961-006: 850 mg, 60, R44,40  to be indiv.bas.on gluc.-low.respons.
       diet with reg.carbohydr. intake dur.day& in energy restrict.diet for   897961-014: 850 mg, 300, R222,00  Max.recomm.dos: Dos.of more than 45 mg once dly. not stud. No
       overweight pts., condits.caus.dehydrat., infect./ trauma/ low calor.  721443-001: 1 000 mg, 60, R49,91  studies of more than 30 mg/day in combin.ther.effect.
       diet, annual monit.of Vit B12 & folic acid, poss.dos.adjustm.of an-  Dosage: Admin.in div.dos.with meals. Grad.incr. may improve GI tol.  Contraindications: Hepat.impairm./act.liv.dis., ser. transamin.lev.
       ticoags.& incr. INR determinat.freq., excret.in human breast milk &   Adults: Init.dos. 500 mg 2-3xdly or 850 mg or 1000 mg 2xdly.with   &gt;2,5x upper norm. limit., CF/ hist.thereof, pregn., lactat., type 1 diab.
       as data limit.breast feed.not recomm., should not be used in childr.  or aft.food. Aft.10-15 days adjust dos.to bld.gluc.measurem. If con-  mellit., diabet. ketoacidos., curr.bladd.Ca/hist.thereof, uninvestig.
       Interactions: Incr.lact.acidos.risk.in ac.alchol. intoxicat.& concom.  trol incomplete caut.incr.to max.2550 mg dly.with poss. reduc.dos.  macroscop.haematur., safety & effic.in childr. not est.
       meds.poss. affect.ren.funct., accumulat.risk with iodinat.contrast   once control obt.  Side effects: Freq: URTI, bronchit., hypoaesthes., bone fract.,
       media incr. lact.acidos.risk, intrins.hyperglycaem.activ.of glucocor-  Childr.& adolesc.from 12 yrs: Usual start.dos. 500-850 mg once   weight gain, hypoglycaem.with metformin & sulphonylur.& with
       tic./ beta-2-agon.& diurets., ACE-inhibit. poss.decr.bld.gluc.lev., con-  dly.dur.or aft.meals. Adjust aft. 10-15 days on basis of bld.gluc.meas-  concom.insul., headache with metformin, dizzin.with sulphonylur.,
       com.OCT1 & OCT2 inhibit. or induc.poss.incr.metform.plasma conc.   urem. Max. recomm.dos.is 2 000 mg dly in 2-3 div.dos.  vis. disturbs.with monother.& metformin, HF & dyspn. with insul.,
       esp. in pres.of ren.impairm., reduc.clear.with cimetidine, warfar.ac-  Contraindications: Diabet.ketoacidos., ren. impairm., ac.condit.  arthralg.with concom.metform./ metform. & sulphonylur., anaem./
       tiv.dimin., poss. hypoglycaem. with concom.sulphonylurea, Vit.B12   with potent.to alt.ren.funct.eg. dehydrat./sev.infect./shock/intra-  haematur./erect. dysfunt. with concom.metform. Less freq: Sinusit.,
       malabsorpt.poss.with long term treatm.  vasc.iodinat. contrast agents, ac./chron.dis.which may cause tiss.   bladd.Ca, insomn., hypoglycaem./incr appet/ headache/vis.disturbs./
       METORED, Ranbaxy [P/S]        hypox.eg.card.or resp.fail./rec.MI/shock/ pancreatit., hepat.insuf-  vertigo/sweat.with sulphonylur., flatul.with metform./sulphonylur.&
                                                                  with insul., glucosur./ proteinur./fatig./incr. lact.dehydrogen. with
                                     fic., ac.alcoh.intoxicat., alcohol., pregn.& lactat., childr.und.12 yrs.
       Metformin HCl.                                             sulphonylur. Freq.not known: Hypersens./allerg.reacts., macul.oed.
       Indications: Type II diab.mellit.when diet.fail & esp.if pt.is over-  Side effects: Lactic acidos., megaloblast.anaem., hypersens.,   Warnings and special precautions: Liv.funct. monit. bef. init.
                                     decr.vit B 12 & folic acid absorpt., hypoglycaem., anorex., N&V,
       weight, alone as init.therap./ combinat.ther.with sulphonylu-  ther.then 2 mnthly for 1 yr. & per. theraft./if sympt.occur indic.liv.
       rea or insul.                 constipat.,diarrh., abdom. pain, metallic taste, sev.cholestat.hep-  dysfunct., hypoglycaem. risk with concom.insul./oral combin. ther.,
                                     atit., liv. funct.abnormalit., erythema, prurit., urticar.
       (S3) TABS, 41/21.2/1089, 1090, 1091  Special precautions: Lact.acidos.risk fact., monit. ren.funct., do   poss.resumpt.of ovulat.in pre-menopaus. anovulat. insul.resist.pts.&
       711636-001: 500 mg, 90, R46,89  not admin.bef./at the time of/until 48 hrs.aft.iodinat. contrast mat.  theref.adeq. contracept. advis., fluid retent.poss.lead. to/ exacerb.
       711638-001: 850 mg, 60, R57,02  admin., discont. 48 hrs.bef.gen.anaesthes.& resume only aft. 48   HF alone or with concom.other antidiab. agents, init.ther.with low.
       711773-001: 1 000 mg, 60, R60,61  hrs., no long term data on growth & puberty in childr.over 12 yrs.,   dos.& incr.grad.in pts. with CCF risk fact., monit.pts.for HF S&S/
       Dosage: Admin.in div.dos.with meals.  avoid alcohol, reg.FBC, elderly bas.on ren.funct., reg.bld.gluc monit.,   weight gain/ oed. esp.those with reduc.card.reserve & concom. in-
       Adults: Init. 500 mg 3x.dly with/aft.food.Aft.10-15 days incr.to 850-  stabil. pts.on concom.insul.in hosp., alert.pts.to poss. hypoglycaem.  sul./NSAIDs incl.COX-2 inhib., discont. ther. if card.status worsen.,
       1000 mg 2x/day. If contr. incompl.caut.incr.to max.3 g /dly.poss.re-  risk when combin.with other antidiabet. agents.  cons.benef.vs.risk in elderly bef./dur.ther., eval.bladd.Ca risk fact.
       duc. dos.once contr.achiev.   Drug interactions: Incr.lact.acidos.risk in ac. alcoh. intoxicat., poss.  bef. init.ther., unexpl.macroscop. haematur./dysur./ urin. urgen.
       Contraindications: Diabet.ketoacidos./-pre-coma or hist.thereof,   ren.fail.with intravasc. iodinat. contrast agents, glucocorticoids/be-  devel.dur.treatm., discont.if ALT incr.to 2,5x basel./jaund.observ.,
       ren.fail./imp.ren.funct., pancreatit., chron.liv.dis., hist.of/states as-  ta-2-agon. & diuret.have intrinsic.hyperglycaem.activ., ACE inhibit.  dos.relat.weight gain alone/ in combin.with other hypoglycaem.,
       soc. with lactat.acidos., CF, recent MI, hypox.assoc. condits., hepat.  may decr.bld.gluc.lev., cimetid.reduc. ren. clear., activ.of warfar.di-  onset/ worsen. macul.oed.with decr.vis.acuit., incr.bone fract. risk
       insuffic., ac.alcohol.intoxicat., alcohol., safety in pregn.& lactat.  minish., hyoglycaem. with concom.sulphonylurea, GI malabsorpt.  in women/men dur.longt.ther., strict diet foll./ reg.bld.gluc.& glyco-
       not est., safety & effic.in childr.not est., type 1 diab.mellit.in childr.  of vit. B 12 & folic acid.  sylat. Hb test, meds. requirem. may change dur.stress.per.eg. fev./
       Side effects: Lact.acidos., megaloblast. anaem., metal.taste, GI   infect./ trauma/surg., unusual.rapid weight incr./ oed., shortn.of
       disturbs., ketoacidos., ketonur., sev. cholestat.hepatit., hypers-  NOVONORM, Novo Nordisk [P/S]  breath/other HF sympt., lact.intol.
       ens., hypoglycaem.            Repaglinide.                 Interactions: Poss.reduc.effic.of OC’s, AUC incr. with gemfibrozil,
       Special precautions: Discont.& hospitalis. immed. if metabol.  Indications: Adjunct.to diet & exerc.to lower bld.gluc.in type 2 dia-  decr.AUC with CYP2CB induc. eg.rifampicin, ketoconazole decr.me-
       acidos.suspect., monit.ren. funct. reg.esp.diabet./elderly, condits.  bet.mellit. May be combined with metformin when exerc./diet/repa-  tabol.theref. more freq.glycaem.contr.monit.
       where ren. funct. may become imp., incr.cardiovasc.mortal. compar.   glinide/ metformin alone is inadeq.Combinat.ther.with insulin in type
       to diet alone/diet + insul.ther., discont. ther. prior intravasc.admin.  2 diab.when control not adeq.on sulphonylureas/repaglinide alone.  ROMIDAB, Aurobindo [P/S]
       of iodinat.contrast materials reinstit.until 48 hr.afterwards, discont.   (S3) TABS. 33/21.2/0078, 0079, 0080.  Metformin HCl.
       48 hrs.bef. elect.surg., contin.diet with reg. distribut. of carbohydr.  861324-005: 0,5 mg, 90, R127,43  Indications: Type II diab.mellit.in adults when diet fail. & esp.if
       intake dur.day, contin. energy-restrict.diet in overweight pts., avoid   861332-008: 1 mg, 90, R259,68  pt.is overweight, as init. monother./ combinat.ther.with other oral
       alcoh. & alcoh.contain.meds., not advis.in condits. caus.dehydrat./  861340-019: 2 mg, 90, R409,96  antidiab. agents or insul.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page329.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page325.html">325</a>&nbsp;&nbsp;&nbsp;<a href="page326.html">326</a>&nbsp;&nbsp;&nbsp;<a href="page327.html">327</a>&nbsp;&nbsp;&nbsp;<a href="page328.html">328</a>&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>&nbsp;&nbsp;&nbsp;<a href="page330.html">330</a>&nbsp;&nbsp;&nbsp;<a href="page331.html">331</a>&nbsp;&nbsp;&nbsp;<a href="page332.html">332</a>&nbsp;&nbsp;&nbsp;<a href="page333.html">333</a>&nbsp;&nbsp;&nbsp;<a href="page334.html">334</a>&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>
             </td>
             <td width="35%"><a href="page331.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page331.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
